Ticagrelor

Trade names

BRILINTA

BRILIQUE

Actions

• Reversible P2Y12 receptor antagonist.

Route of Administration

Oral

Bioavailability

36%

Plasma protein binding

<99.7%

Time to peak plasma concentration

1.5 h

Time to plasma steady state

30 min to 2 h

Half-life

7 h

Elimination

Biliary

Duration of action

5 days

Reversible platelet inhibition

Yes

Recommended dose

Loading dose: 180 mg

Maintenance dose: 90 mg twice daily

After one year administer 60 mg twice daily.

Do not administer ticagrelor with another oral P2Y12 receptor inhibitor.

Renal impairment

No dose adjustment is necessary. No data exist on the use of ticagrelor in dialysis patients therefore its use is not recommended.

Discontinuation before invasive procedures

7 days